Updated Turkish guidelines for the management of psoriasis with biologic agents

References (13)

1. Gottlieb AB, Dann F, Menter A: Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563-72
2. Fortune DG, Richards HL, Griffiths CE: Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005;23:681-94
3. Delaporte E: Immune-mediated inflammatory diseases and psoriasis. Ann Dermatol Venereol 2008;135:269-74
4. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X et al.: The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-9
5. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7
6. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T: The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4
7. Fouéré S, Adjadj L, Pawin H: How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005;19:3:2-6
8. Derkx B, Taminiau J, Radema S et al.: Tumour-necrosis-factor antibody treatment in Crohn’s disease. L.ancet 1993; 342:173-4
9. Mease PJ, Goffe BS, Metz J, et al.: Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000; 356:385-90
10. Chaudhari U, Romano P, Mulcahy LD et al.: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet 2001;357:1842-7
11. Dharamsi JW, Bhosle M, Balkrishnan R, Yentzer BA, Feldman SR: Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors fopatients with severe psoriasis. Br J Dermatol 2009; 161:605-16
12. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D et al: British Association of Dermatologists: British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Dermatol 2005;153:486-97
13. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M et al.: German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-38. 14. aMenter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biolo- gics. J Am Ac